Risk of Cardiovascular Disease in Cancer Survivors after Systemic Treatment: A Population-Based Cohort Study
Authors' conclusion
Several cardiovascular disease risks were elevated among cancer survivors, with substantial variation by cancer type and treatment.
Study context
- Population
- Cancer survivors previously treated with systemic cancer therapy, Danish population-based registries
- Participants
- 91,407 vs 457,035
- Exposure
- Cancer survivors after systemic treatment vs matched cancer-free individuals
- Cancer survivorsn = 91,407
- Matched individualsn = 457,035reference
- Outcome
- Risk of CVD
- Follow-up
- Up to 5 years from index date (3 years after diagnosis)
Methodological detailspopulation-based, Danish registries, matched (birth year, sex, calendar year)
- Population-based
- Danish registries
- Matched (birth year, sex, calendar year)
Main finding
As reported in the abstract
Cancer survivors vs Matched individualsHazard ratio (95% CI)
HF or cardiomyopathy
1.08(1.02–1.15)
VTE
1.50(1.41–1.61)
Pericarditis, endocarditis or myocarditis
1.30(1.11–1.52)
Kidney failure
1.17(1.10–1.25)
Observational data: associations, not effects.
Further findings
CVD risks by cancer type and treatment agent (subgroups)
- Estimates varied substantially by cancer type and treatment agent
- VTE risk increased across nearly all cancer types; hypertension risk elevated for none
- Ischemic heart disease risk increased only among lung cancer survivors
- Stroke associated with platinum compounds but not other systemic treatments
Original publication
Risk of Cardiovascular Disease in Cancer Survivors after Systemic Treatment: A Population-Based Cohort Study. JACC CardioOncol. Published June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →